Medical treatment of vesicoureteral reflux detected in infancy.
Between 1970 and 1982, 41 neonates and infants with grades II and III vesicoureteral reflux (international classification) but with no medical or urological complications were treated medically and followed for an average of 7.5 years. In 33 of the 41 patients the vesicoureteral reflux resolved (group 1) and in 8 it persisted (group 2). The severity and frequency of urinary infection decreased to a greater degree in group 1 (p less than 0.0005) than in group 2 (p less than 0.05). There was no difference in endogenous creatinine clearance between the 2 groups. Comparison of kidney length and bipolar parenchymal thickness revealed that bipolar parenchymal thickness was significantly less in group 2 patients (p less than 0.01). Body weight tended to increase in both groups but it was greater in group 1. In both groups height was lower at the time of detection of reflux and it approached nearly normal values during followup. It is tempting to conclude that early recognition of mild forms of vesicoureteral reflux (grades II and III) and systematic medical treatment can preserve renal function and promote renal and somatic growth. However, this tendency is less pronounced in patients with persistent reflux.
Pintér
A B
AB
Surgical Unit of Children's Department, University Medical School of Pécs, Hungary.
Jászai
V
V
Dóber
I
I
D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use; D001827:Body Height; D001835:Body Weight; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007668:Kidney / Q000503:physiopathology; D007677:Kidney Function Tests; D008297:Male; D013997:Time Factors; D014552:Urinary Tract Infections / Q000517:prevention & control; D014718:Vesico-Ureteral Reflux / Q000503:physiopathology / Q000628:therapy*
D000892:Anti-Infective Agents, Urinary